TradeUP Acquisition (UPTDW) Financials

Estrella Immunopharma remains a pre-revenue biotechnology company with no reported revenue in the periods provided. The company continues to fund research and development primarily through equity financing while posting recurring operating losses and consuming cash.

There are some signs of improving expense control. In Q2 2026, operating expenses declined to $2.1 million from $5.5 million in Q2 2025 and $4.8 million in Q3 2025. Research and development spending fell to $1.4 million from $4.7 million a year earlier, while SG&A declined to $684,000 from $884,000. However, the lower spending has not yet translated into revenue or profitability.

• Operating expenses decreased substantially. Q2 2026 operating expenses were $2.08 million, down approximately 62% year over year, which could extend the company’s financial runway if the lower spending level continues.
• Quarterly operating cash burn improved compared with Q1 2026. Net cash used in operating activities was $1.78 million in Q2 2026 versus $6.70 million in Q1 2026, helped in part by more favorable changes in operating assets and liabilities.
• The company raised approximately $8.0 million through common equity issuance in Q1 2026. This financing temporarily supported cash resources and helped offset operating losses during the quarter.
• Accrued liabilities declined from their Q3 2025 peak. Accrued expenses fell to $8.30 million in Q2 2026 from $12.89 million in Q3 2025, although the balance remains very large relative to the company’s assets.

• Estrella’s business remains entirely pre-revenue. The company reported zero revenue, zero cost of revenue and zero gross profit in every income statement period supplied, so future value remains dependent on clinical, regulatory and commercialization progress rather than current operating performance.
• Research and development spending has been volatile. R&D expense ranged from $75,000 in Q2 2023 to $4.66 million in Q2 2025 before falling to $1.40 million in Q2 2026. The decline may reflect changing development activity, but the statements alone do not indicate whether it represents improved efficiency or reduced program investment.
• Several historical figures were restated or calculated. Comparisons should be treated cautiously because certain 2024 and 2025 income and cash-flow statements were marked as restated or calculated, and some fiscal-period labels do not align cleanly with the reported end dates.

• Liquidity has deteriorated sharply. Cash and equivalents fell to just $146,670 at June 30, 2026, from $1.93 million at March 31, 2026 and $4.73 million in the comparable historical balance-sheet data. With Q2 operating cash use of $1.78 million, reported cash alone provides very limited funding capacity.
• The company continues to generate significant losses. Q2 2026 net loss was $2.31 million, or $0.05 per share, following a $2.29 million loss in Q1 2026. Estrella has reported losses in every income statement period provided.
• Shareholders’ equity is deeply negative. Total equity was negative $7.43 million at June 30, 2026, compared with negative $5.27 million in Q1 2026 and positive equity in earlier 2024 periods. Total liabilities of $9.26 million were roughly five times total assets of $1.82 million.
• Estrella remains dependent on additional financing. Q2 2026 generated virtually no financing cash flow, while the company used $1.78 million for operations. Future equity or other financing may be necessary, creating dilution and financing-risk concerns.
• Share dilution has been substantial. Weighted-average basic shares increased from approximately 1.1 million in the Q1 2024 data to 43.0 million in Q2 2026, reflecting the company’s reliance on equity issuance and reducing each existing shareholder’s proportional ownership.
• Operating liabilities remain high relative to available resources. Accounts payable, accrued expenses and other current liabilities totaled approximately $9.26 million in Q2 2026, far exceeding cash and equivalents and raising questions about the company’s ability to meet obligations without new capital.

Overall, the financial statements show lower quarterly spending but worsening balance-sheet pressure. The improved expense profile is a potential positive, but it is outweighed by minimal cash, recurring losses, negative equity, no revenue and continued dependence on external financing. Investors should closely monitor cash-raising activity, operating burn, accrued liabilities and progress toward clinical or commercial milestones.